All In Biotech

Drug Trial Radar · NCT03535558

Fluoroquinolone Associated Disability

Last checked: Nov 19, 2026Latest source record: Jan 29, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

239,306

Actual

Start

May 17, 2018

Primary completion

Dec 31, 2018

Study completion Dec 31, 2018

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
May 24, 2018

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to: 1) describe drug utilization for Fluoroquinolone(FQ), Azithromycin (AZ) and Sulfamethoxazole/Trimethoprim(ST) in the entire Truven MarketScan Commercial Claims and Encounters database (CCAE) database, and specifically among individuals in the Health and Productivity Management (HPM) during the observation period; 2) describe the rate of disability associated with 2 or more System Organ Class adverse events (SOC AEs) and exposure to FQs for several acute, uncomplicated indications; and 3) compare the rates of disability for 2 or more SOC AEs and exposure to FQs and AZ/ST for the same indications.

Conditions

  • Bronchitis
  • Sinusitis
  • Urinary Tract Infections

Interventions

  • Fluoroquinolone (FQ)Drug

    Participants exposed to an oral FQ will be observed. The oral FQ included are Levofloxacin, Ciprofloxacin, Moxifloxacin, Ofloxacin, Gemifloxacin. Participants will not receive any intervention as a part of this study.

  • Azithromycin (AZ)Drug

    Participants exposed to an oral AZ will be observed. Participants will not receive any intervention as a part of this study.

  • Sulfamethoxazole/Trimethoprim (ST) Fixed Dose CombinationDrug

    Participants exposed to an oral ST will be observed. Participants will not receive any intervention as a part of this study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Disability in Temporal ProximityTime frame: Up to 120 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Janssen Investigative Site

    Titusville, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.